← Back
$AMLX All transactions

Amylyx Pharmaceuticals, Inc.

A

$ Value

$0

Shares

95,990

Price

$0

Filed

Mar 9

Insider

Name

FRATES JAMES M

Title

Chief Financial Officer

CIK

0001235598

Roles

Officer

Transaction Details

Transaction Date

2026-03-05

Code

A

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

261,628

Footnotes

The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. | Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. | Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. | Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. | 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Filing Info

Accession No.

0001193125-26-098438

Form Type

4

Issuer CIK

0001658551

FRATES JAMES M's History

Date Ticker Type Value
2026-03-05 AMLX A $0
2026-03-05 AMLX A $0
2026-03-02 AMLX $115K
2026-02-02 AMLX $52K
2026-01-06 AMLX $37K
2025-09-30 AMLX $155K
2025-07-31 SAGE U
2025-07-31 SAGE D
2025-07-31 SAGE D
2025-06-11 SAGE A $0

Other Insiders at AMLX (90d)

Insider Bought Sold Last
FRATES JAMES M
Chief Financial Officer
$167K 2026-03-05
Bedrosian Camille L
Chief Medical Officer
$94K 2026-03-05
Klee Justin B.
Co-Chief Executive Officer
$651K 2026-03-05
Cohen Joshua B
Co-Chief Executive Officer
$652K 2026-03-05
Mazzariello Gina
Chief Legal Officer
$198K 2026-03-05